139 related articles for article (PubMed ID: 1910957)
1. The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime.
Steiniche T; Hasling C; Charles P; Eriksen EF; Melsen F; Mosekilde L
Bone; 1991; 12(3):155-63. PubMed ID: 1910957
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.
Hasling C; Charles P; Jensen FT; Mosekilde L
Osteoporos Int; 1994 Jul; 4(4):191-203. PubMed ID: 7949749
[TBL] [Abstract][Full Text] [Related]
3. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.
Storm T; Steiniche T; Thamsborg G; Melsen F
J Bone Miner Res; 1993 Feb; 8(2):199-208. PubMed ID: 8442438
[TBL] [Abstract][Full Text] [Related]
4. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study.
Pacifici R; McMurtry C; Vered I; Rupich R; Avioli LV
J Clin Endocrinol Metab; 1988 Apr; 66(4):747-53. PubMed ID: 3126214
[TBL] [Abstract][Full Text] [Related]
5. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
Miller PD; Watts NB; Licata AA; Harris ST; Genant HK; Wasnich RD; Ross PD; Jackson RD; Hoseyni MS; Schoenfeld SL; Valent DJ; Chesnut CH
Am J Med; 1997 Dec; 103(6):468-76. PubMed ID: 9428829
[TBL] [Abstract][Full Text] [Related]
6. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
Harris ST; Watts NB; Jackson RD; Genant HK; Wasnich RD; Ross P; Miller PD; Licata AA; Chesnut CH
Am J Med; 1993 Dec; 95(6):557-67. PubMed ID: 8259772
[TBL] [Abstract][Full Text] [Related]
7. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis.
Steiniche T; Hasling C; Charles P; Eriksen EF; Mosekilde L; Melsen F
Bone; 1989; 10(5):313-20. PubMed ID: 2690898
[TBL] [Abstract][Full Text] [Related]
8. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
9. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
[TBL] [Abstract][Full Text] [Related]
10. Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis.
Thomas T; Lafage MH; Alexandre C
J Rheumatol; 1995 Nov; 22(11):2183-5. PubMed ID: 8596168
[TBL] [Abstract][Full Text] [Related]
11. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
12. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
[TBL] [Abstract][Full Text] [Related]
13. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
Fogelman I; Herd RJ; Blake GM; Balena R
Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
[TBL] [Abstract][Full Text] [Related]
14. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up).
Meunier PJ; Confavreux E; Tupinon I; Hardouin C; Delmas PD; Balena R
J Clin Endocrinol Metab; 1997 Sep; 82(9):2784-91. PubMed ID: 9284696
[TBL] [Abstract][Full Text] [Related]
15. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study.
Lyritis GP; Tsakalakos N; Paspati I; Skarantavos G; Galanos A; Androulakis C
Clin Rheumatol; 1997 Jun; 16(4):354-60. PubMed ID: 9259248
[TBL] [Abstract][Full Text] [Related]
16. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures.
Anderson FH; Francis RM; Bishop JC; Rawlings DJ
Age Ageing; 1997 Sep; 26(5):359-65. PubMed ID: 9351480
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of osteoporosis using the ADFR schedule (especially with parathyroid hormone and etidronate)].
Ziegler R
Internist (Berl); 1991 Feb; 32(2):76-9. PubMed ID: 1903362
[No Abstract] [Full Text] [Related]
18. Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty.
Yamaguchi K; Masuhara K; Yamasaki S; Fuji T; Seino Y
Bone; 2004 Jul; 35(1):217-23. PubMed ID: 15207760
[TBL] [Abstract][Full Text] [Related]
19. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
20. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
